

# Textbook of OBSTETRICS

**Including Perinatology and Contraception** 

# Contents

1	Anatomy of Female Reproductive Organs	1
	<ul> <li>External Genitalia 1; • Mons Veneris 2; • Labia Majora 2; • Labia Minora 2; • Clitoris 2; • Vestibule 2;</li> <li>Perineum 3; Internal Genitalia 3; • Vagina 3; • Uterus 4; • Fallopian Tube 6; • Ovary 7; • Muscle and Fascia in Relation to the Pelvic Organs 9; • Pelvic Floor 9; • Perineum 10; • Pelvic Fascia 11; I Pelvic Cellular Tissue 11; I Female Urethra 12; I Urinary Bladder 12; I Pelvic Ureter 12; I Breasts 13</li> </ul>	
2	Fundamentals of Reproduction	16
	■ Gametogenesis 16; • Oogenesis 16; • Spermatogenesis 18; ■ Ovulation 18; ■ Fertilization 19; • Morula 20; • Blastocyst 20; ■ Implantation 21; • Trophoblast 21; ■ Decidua 22; ■ Chorion and Chorionic Villi 23; ■ Development of Inner Cell Mass 23	
3	Placenta and Fetal Membranes	26
	<ul> <li>Placenta 26; • Development 26; • Placenta at Term 27; • Structures 27; • Placental Circulation 29;</li> <li>Placental Aging 31; • Placental Function 32; • Fetal Membranes 34; • Amniotic Cavity and Amnion 34;</li> <li>• Amniotic Fluid 34; • Umbilical Cord 36</li> </ul>	
4	The Fetus	38
	■ Fetal Physiology 39; ■ Fetal Circulation 40; • Changes in the Fetal Circulation at Birth 41	
5	Physiological Changes During Pregnancy	43
	<ul> <li>Genital Organs 43;</li> <li>Uterus 43;</li> <li>Breasts 46;</li> <li>Cutaneous Changes 46;</li> <li>Weight Gain 47;</li> <li>Body</li> <li>Water Metabolism 47;</li> <li>Hematological Changes 48;</li> <li>Cardiovascular System 49;</li> <li>Metabolic Changes 50;</li> <li>Systemic Changes 51</li> </ul>	
6	Endocrinology in Relation to Reproduction	55
	<ul> <li>Maturation of Graafian Follicles and Ovulation 55;</li> <li>Maintenance of Corpus Luteum after Fertilization 55;</li> <li>Placental Endocrinology 55;</li> <li>Hormones of Placenta 55;</li> <li>Protein Hormones 55;</li> <li>Steroidal Hormones 57;</li> <li>Diagnostic Value of Placental Hormones 58;</li> <li>Changes in Endocrine Glands During Pregnancy 58;</li> <li>Pituitary Gland 58;</li> <li>Adrenal Cortex 59;</li> <li>Parathyroid Gland 59;</li> <li>Pancreas 59;</li> <li>Hormonal Influences Necessary for Maintenance of Lactation 59</li> </ul>	
7	Diagnosis of Pregnancy	61
	■ First Trimester (First 12 Weeks) 61; ■ Second Trimester (13–28 Weeks) 63; ■ Last Trimester (29–40 Weeks) 65; ■ Differential Diagnosis of Pregnancy 66; ■ Chronological Appearance of Specific Symptoms and Signs of Pregnancy 66; ■ Signs of Previous Childbirth 66; ■ Estimation of Gestational Age and Prediction of Expected Date of Delivery 67; ■ Estimation of Fetal Weight 67	
8	The Fetus-in-Utero	69
	<ul> <li>Causes of Preponderance of Longitudinal Lie and Cephalic Presentation 71;</li> <li>Methods of Obstetrical Examination 71</li> </ul>	
9	Fetal Skull and Maternal Pelvis	76
	<ul> <li>Fetal Skull 76;</li> <li>Pelvis 79;</li> <li>False Pelvis 79;</li> <li>True Pelvis 80;</li> <li>Inlet 80;</li> <li>Cavity 82;</li> <li>Outlet 82</li> <li>Midpelvis 83;</li> <li>Physiological Enlargement of Pelvis during Pregnancy and Labor 85</li> </ul>	

iii Con	itents	
iii cor	itents	
10	Antenatal Care, Preconceptional Counseling and Care	86
	<ul> <li>Procedure at the First Visit 86;</li> <li>History Taking 86;</li> <li>Examination 88;</li> <li>Procedure at the Subsequent Visits 90;</li> <li>Antenatal Advice 90;</li> <li>Minor Ailments in Pregnancy 92;</li> <li>Values of Antenatal Care 93;</li> <li>Preconceptional Counseling and Care 94</li> </ul>	
11	Antenatal Assessment of Fetal Wellbeing	95
	<ul> <li>Clinical Evaluation of Fetal Wellbeing at Antenatal Clinic 95;</li> <li>First Visit 95;</li> <li>Subsequent Visits 95;</li> <li>Special Investigations 96;</li> <li>Early Pregnancy 96;</li> <li>Antepartum Fetal Surveillance (Late Pregnancy) 96;</li> <li>Other Investigations in Late Pregnancy 99</li> </ul>	
12	Prenatal Genetic Counseling, Screening and Diagnosis	102
	<ul> <li>Prenatal Genetic Screening 102;</li> <li>Prenatal Diagnosis 104;</li> <li>Invasive Procedures for Prenatal Diagnosis</li> <li>Chorionic Villus Sampling 104;</li> <li>Amniocentesis 105;</li> <li>Cordocentesis or Percutaneous Umbilical Blood</li> <li>Sampling 105;</li> <li>Noninvasive Method of Prenatal Testing from Maternal Plasma/Blood 106;</li> <li>Fetal DNA 10</li> </ul>	
13	Normal Labor: Intrapartum Care for a Positive Child Birth Experience (WHO)	108
	<ul> <li>Labor 108; • Onset 108; • Contractile System of the Myometrium 109; • Physiology of Normal Labor</li> <li>Events in First Stage of Labor 113; • Events in Second Stage of Labor 115; • Events in Third Stage of Labor</li> <li>Mechanism of Normal Labor 117; • Anatomy of Labor 120; • Clinical Course of First Stage of Labor 121;</li> <li>Clinical Course of Second Stage of Labor 124; • Clinical Course of Third Stage of Labor 125; • Place of</li> <li>Delivery 126; • Management of Normal Labor 126; • Management of First Stage of Labor 127; • Management of Second Stage of Labor 129; • Immediate Care of the Newborn 131; • Management of Third Stage of Labor</li> <li>Active Management of Third Stage of Labor (AMTSL) 132; • Labor Care Guide (WHO) 136</li> </ul>	116; ent
14	Normal Puerperium	139
	<ul> <li>Involution of the Uterus 139;</li> <li>Involution of Other Pelvic Structures 140;</li> <li>Lochia 141;</li> <li>General Physiological Changes 141;</li> <li>Lactation 142;</li> <li>Physiology of Lactation 143;</li> <li>Management of Normal Puerperium 144;</li> <li>Management of Ailments 145;</li> <li>Postnatal Care 147</li> </ul>	
1.5	Nausea and Vomiting in Pregnancy	149
	■ Vomiting in Pregnancy 149; ■ Hyperemesis Gravidarum 149; • Clinical Course 150; • Management 1	51
16	Hemorrhage in Early Pregnancy	153
	<ul> <li>Spontaneous Abortion (Miscarriage) 153;</li> <li>Threatened Miscarriage 155;</li> <li>Lomplete Miscarriage 156;</li> <li>Incomplete Miscarriage 157;</li> <li>Missed Miscarriage 157;</li> <li>Septic Abortion 158;</li> <li>Management 159;</li> <li>Recurrent Miscarriage 160;</li> <li>Cervical Incompetence 162;</li> <li>Induction of Abortion 166;</li> <li>Medical Termination of Pregnancy (MTP) 166;</li> <li>Methods of Termination of Pregnancy 166;</li> <li>Recommendations 167;</li> <li>First Trimester Termination of Pregnancy 167;</li> <li>Midtrimester Termination of Pregnancy 170;</li> <li>Tubal Pregnancy 170;</li> <li>Acute Ectopic Pregnancy 172;</li> <li>Unruptured Tubal Ectopic 172;</li> <li>Diagnosis of Ectopic Pregnancy 173;</li> <li>Managemen of Ectopic Pregnancy 174;</li> <li>Interstitial 178;</li> <li>Abdominal 178;</li> <li>Ovarian 179;</li> <li>Cornual 179;</li> <li>Cervical 180;</li> <li>Pregnancy of Unknown Location 180;</li> <li>Cesarean Scar Pregnancy 180;</li> <li>Heterotopic</li> </ul>	

## Multiple Pregnancy, Amniotic Fluid Disorders, Abnormalities of Placenta and Cord

Disease 188

190

■ Twins 190; • Diagnosis 192; • Complications 194; • Prognosis 196; • Complications of Monochorionic Twins 196; ■ Antenatal Management 197; ■ Management during Labor 198; ■ Triplets, Quadruplets, etc. 200; ■ Amniotic Fluid Disorders 202; • Polyhydramnios 202; • Etiology 202; • Complications 203; ■ Management of Hydramnios 204; • Acute Polyhydramnios 205; • Oligohydramnios 205; ■ Abnormalities of Placenta and Cord 206; • Placental Abnormalities 206; • Cord Abnormalities 208

Pregnancy 181; Gestational Trophoblastic Diseases (GTD) 182; Hydatidiform Mole 182; Partial or Incomplete Mole 187; Placental Site Trophoblastic Tumor (PSTT) 188; Persistent Gestational Trophoblastic

xix

18	Hypertensive Disorders in Pregnancy	209
	<ul> <li>Pre-eclampsia (PE) 209; • Diagnostic Criteria 210; • Etiopathogenesis 210; • Pathophysiology 211;</li> <li>Clinical Types 213; • Clinical Features 213; • Complications 215; • Screening Tests for Prediction and Prevention 215; • Prophylactic Measures for Prevention 216; • Management of Gestational Hypertension and Pre-eclampsia 217; • Acute Fulminant Pre-eclampsia 220; • Eclampsia 221; • Clinical Features 222; • Prognosis 222; • Management 222; • Chronic Hypertension in Pregnancy 226;</li> <li>Essential Hypertension in Pregnancy 226; • Chronic Renal Diseases in Pregnancy 227; • Pregnancy after Renal Transplant 228</li> </ul>	
19	Antepartum Hemorrhage	230
	<ul> <li>Placenta Previa 230;</li> <li>Etiology 230;</li> <li>Clinical Features 232;</li> <li>Differential Diagnosis 233;</li> <li>Complications 233;</li> <li>Prognosis 235;</li> <li>Management 235;</li> <li>Practical Guide for Cesarean Delivery 238;</li> <li>Practical Approach to Lower Segment CD for Placenta Previa 238;</li> <li>Practical Guide to Lower Segment Approach for Placenta Previa Accreta 238;</li> <li>Abruptio Placentae 239;</li> <li>Clinical Features 241;</li> <li>Management 241;</li> <li>Treatment in the Hospital 242;</li> <li>Indeterminate Bleeding 244</li> </ul>	
20	Medical and Surgical Illnesses Complicating Pregnancy	246
	<ul> <li>Hematological Disorders in Pregnancy 246; • Anemia in Pregnancy 246; • Iron Deficiency Anemia 248;</li> <li>Megaloblastic Anemia 253; • Dimorphic Anemia 255; • Aplastic Anemia 255; • Hemoglobinopathies 25</li> <li>Sickle Cell Hemoglobinopathies 256; • Thalassemia Syndromes 257; • Platelet Disorders 257; • Heart Disease in Pregnancy 259; • General Management 260; • Management during Labor 261; • Specific Hear Disease during Pregnancy and the Management 262; • Diabetes Mellitus and Pregnancy 265; • Gestational Diabetes Mellitus (GDM) 265; • Overt Diabetes 267; • Thyroid Dysfunction and Pregnancy 273; • Jaundice in Pregnancy 275; • Viral Hepatitis 275; • Epilepsy in Pregnancy 277; • Asthma in Pregnancy 278;</li> <li>Systemic Lupus Erythematosus (SLE) 280; • Tuberculosis in Pregnancy 280; • Syphilis in Pregnancy 281;</li> <li>Parasitic and Protozoal Infestations in Pregnancy 283; • Pyelonephritis in Pregnancy 284; • Asymptomatic Bacteriuria (ASB) 285; • Viral Infections in Pregnancy 286; • Human Immunodeficiency Virus (HIV) Infection and Acquired Immunodeficiency Syndrome (AIDS) 288; • COVID-19 in Pregnancy 291; • Surgical Illness during Pregnancy 291; • Acute Pain in Abdomen during Pregnancy 292; • Headache in Pregnancy 293; • Acute Fatty Liver in Pregnancy 293</li> </ul>	t e
21	Gynecological Disorders in Pregnancy	294
	<ul> <li>Abnormal Vaginal Discharge 294;</li> <li>Congenital Malformation of the Uterus and Vagina 294;</li> <li>Carcinoma Cervix with Pregnancy 295;</li> <li>Treatment 295;</li> <li>Leiomyomas with Pregnancy 296;</li> <li>Treatment 296;</li> <li>Ovarian Tumor in Pregnancy 296;</li> <li>Retroverted Gravid Uterus 297;</li> <li>Morbid Anatomic Changes 298;</li> <li>Treatment 298;</li> <li>Genital Prolapse in Pregnancy 298;</li> <li>Treatment 298</li> </ul>	
22	Preterm Labor and Birth, Preterm Rupture of the Membranes, Prolonged Pregnancy, Intrauterine Fetal Death	300
	<ul> <li>Preterm Labor and Birth 300; • Etiology 300; • Management of Preterm Labor and Birth 302;</li> <li>Prevention of Preterm Labor 302; • Measures to Arrest Preterm Labor 302; • Management in Labor 302;</li> <li>Prelabor Rupture of the Membranes (PROM) 304; • Management 305; • Prolonged and Post-term Pregnancy 306; • Diagnosis 307; • Management 308; • Intrauterine Fetal Death (IUFD) 310;</li> <li>Etiology 310; • Diagnosis 311; • Recommended Evaluation for a Stillbirth 311; • Management 311</li> </ul>	
23	Complicated Pregnancy	314
	<ul> <li>Pregnancy with Prior Cesarean Delivery (CD) 314; • Integrity of the Scar 314; • Evidences of Scar Rupture (or Scar Dehiscence) during Labor 315; • Management of a Pregnancy with Prior CD 316; • Vaginal Birth after Previous (CD) 316; • Red Cell Alloimmunization 318; • Fetal Affection by the Rh Antibody 320;</li> <li>Manifestations of Hemolytic Disease of the Fetus and Newborn (HDFN) 320; • Prevention of Rh-D Alloimmunization 321; • Antenatal Investigation Protocol of Rh-negative Mothers 323; • Plan of Delivery 32</li> <li>• Prognosis 326; • Exchange Transfusion in the Newborn 326; • Grand Multipara 326; • Elderly Primigravida 327; • Bad Obstetric History (BOH) 328; • Investigations and Management 328;</li> <li>• Obesity in Pregnancy 329</li> </ul>	24;

24 Contracted Pelvis

	<ul> <li>Asymmetrical or Obliquely Contracted Pelvis 333;</li> <li>Mechanism of Labor in Contracted Pelvis with Vertex Presentation 333;</li> <li>Diagnosis of Contracted Pelvis 334;</li> <li>Disproportion 336;</li> <li>Diagnosis of Cephalopelvic Disproportion (CPD) at the Brim 336;</li> <li>Effects of Contracted Pelvis on Pregnancy and Labor 337;</li> <li>Management of Contracted Pelvis (Inlet Contraction) 338;</li> <li>Trial Labor 338;</li> <li>Midpelvic and Outlet Disproportion 339</li> </ul>	t
25	Abnormal Uterine Action	340
	<ul> <li>Uterine Inertia (Hypotonic Uterine Dysfunction) 341;</li> <li>Incoordinate Uterine Action 342;</li> <li>Precipitate Labor 344;</li> <li>Tonic Uterine Contraction and Retraction 344</li> </ul>	
26	Complicated Labor: Malposition, Malpresentation and Cord Prolapse	347
	<ul> <li>Occiput Posterior (OP) Position 347; • Diagnosis 348; • Mechanism of Labor 349; • Course of Labor 351;</li> <li>Management of Labor 351; • Arrested Occiput Posterior Position 352; • Deep Transverse Arrest (DTA) 353;</li> <li>Manual Rotation for Occiput Posterior Position 353; • Breech Presentation 355; • Varieties 355; • Etiology of Breech Presentation 355; • Diagnosis of Breech Presentation 356; • Mechanism of Labor in Breech Presentation 356; • Complications of Vaginal Breech Delivery 358; • Antenatal Management 359;</li> <li>Management of Vaginal Breech Delivery 361; • Assisted Breech Delivery 361; • Management of Complicated Breech Delivery 365; • Face Presentation 367; • Mechanism of Labor 368; • Diagnosis 368;</li> <li>Management 370; • Vaginal Delivery 370; • Brow Presentation 371; • Transverse Lie 371;</li> <li>Diagnosis 372; • Clinical Course of Labor 372; • Management of Shoulder Presentation 374;</li> <li>Unstable Lie 374; • Compound Presentation 374; • Cord Prolapse 375; • Management 376</li> </ul>	
27	Prolonged Labor, Obstructed Labor, Dystocia Caused by Fetal Anomalies	378
	<ul> <li>Prolonged Labor 378;</li> <li>Treatment 380;</li> <li>Obstructed Labor 381;</li> <li>Treatment 382;</li> <li>Shoulder Dystocia 383;</li> <li>Dystocia Caused by Fetal Anomalies 383;</li> <li>Hydrocephalus 383;</li> <li>Neural Tube Defects (NTD) 384;</li> <li>Anencephaly 384;</li> <li>Conjoined Twins 385</li> </ul>	
28	Complications of the Third Stage of Labor	386
	<ul> <li>Postpartum Hemorrhage (PPH) 386;</li> <li>Primary Postpartum Hemorrhage 386;</li> <li>Causes 386;</li> <li>Prevention 387</li> <li>Management of Third-stage Bleeding 388;</li> <li>Steps of Manual Removal of Placenta 388;</li> <li>Management of True Postpartum Hemorrhage 389;</li> <li>Actual Management 390;</li> <li>Secondary Postpartum Hemorrhage 393;</li> <li>Retained Placenta 394;</li> <li>Management 394;</li> <li>Inversion of the Uterus 396</li> </ul>	
29	Injuries to the Birth Canal	398
	<ul> <li>Vulva 398;</li> <li>Perineum 398;</li> <li>Management 398;</li> <li>Vagina 399;</li> <li>Cervix 400;</li> <li>Pelvic Hematoma 400</li> <li>Rupture of the Uterus 401;</li> <li>Etiology 402;</li> <li>Pathology 403;</li> <li>Diagnosis 404;</li> <li>Management 405;</li> <li>Visceral Injuries 405</li> </ul>	;
30	Abnormalities of the Puerperium	407
	<ul> <li>Puerperal Pyrexia 407;</li> <li>Puerperal Sepsis 407;</li> <li>Pathology 408;</li> <li>Clinical Features 408;</li> <li>Investigation of Puerperal Pyrexia 409;</li> <li>Treatment 410;</li> <li>Subinvolution 411;</li> <li>Urinary Complications in Puerperium 411;</li> <li>Prophylaxis and Management 414;</li> <li>Pulmonary Embolism 415;</li> <li>Obstetric Palsies 416;</li> <li>Puerperal Emergencies 416;</li> <li>Psychological Response to Perinatal Deaths and Management 418</li> </ul>	
31	The Term Newborn Infant	419
	<ul> <li>Physical Features of the Newborn 419;</li> <li>Immediate Care of the Newborn 421;</li> <li>Infant Feeding 422;</li> <li>Breastfeeding 423;</li> <li>Artificial Feeding 427;</li> <li>Childhood Immunization Program 428</li> </ul>	
32	Low Birth Weight Baby	429

Preterm Baby 430;
 Complications of a Preterm Neonate 430;
 Management 432;
 Care of a Preterm

Neonate 432; • Fetal Growth Restriction (FGR) 434; • Management 437

331

#### 441 Diseases of the Fetus and the Newborn Perinatal Asphyxia 441; Fetal Respiration 441; Clinical Features 442; Management 443; Respiratory Distress in the Newborn 445; Transient Tachypnea of the Newborn (TTN) 448; Meconium Aspiration Syndrome (MAS) 448; Jaundice of the Newborn 449; Management of Jaundice in the Newborn 451; Hemolytic Disease of the Newborn 452; ABO Group Incompatibility 452; Bleeding Disorders in the Newborn 453; Anemia in the Newborn 453; Seizures in the Newborn 454; Birth Injuries of the Newborn 455; • Injuries to the Head 455; • Intracranial Hemorrhage 456; • Other Injuries 457; Perinatal Infections 458; Mode of Infection 458; Ophthalmia Neonatorum 459; Skin Infections 460; Necrotizing Enterocolitis 461; Mucocutaneous Candidiasis 461; Congenital Malformations and Prenatal Diagnosis 463; • Down's Syndrome (Trisomy 21) 463; • Surgical Emergencies 463; • Nonimmune Fetal Hydrops 465 Pharmacotherapeutics in Obstetrics 467 Oxytocics in Obstetrics 467; Oxytocin 467; Methods of Administration 468; Ergot Derivatives 470; Prostaglandins (PGs) 470; Antihypertensive Therapy 473; Diuretics 473; Tocolytic Agents 473; Anticonvulsants 474; Anticoagulants 474; Maternal Drug Intake and Breastfeeding 475; Fetal Hazards of Maternal Medication during Pregnancy 477; • Teratology and Prescribing in Pregnancy 477; Analgesia and Anesthesia in Obstetrics 479; Anatomical and Physiological Considerations 479; Analgesia during Labor and Delivery 480; Inhalation Methods 481; Regional (Neuraxial) Anesthesia 482; • Infiltration Analgesia 484; • General Anesthesia for Cesarean Section 484 Induction of Labor 487 Methods of Induction of Labor 488; Medical Induction 488; Surgical Induction 490; Low Rupture of the Membranes (LRM) 491; • Stripping the Membranes 491; • Combined Method 492 496 Population Dynamics and Control of Conception Control of Contraception 496; Family Planning 496; Contraception 497; Methods of Contraceptions 497; • Temporary Methods 497; • Intrauterine Contraceptive Devices 497; • Steroidal Contraceptions 504; • Combined Oral Contraceptives (Pills) 504; • Centchroman (Chhaya/Saheli) 509; Progestogen-only Contraceptions 509; Emergency Contraception (CE) 511; Summary of Oral Contraceptives 512; Drug Interaction and Hormonal Contraception 513; Sterilization 513; Couple Counseling 513; Male Sterilization 514; Female Sterilization 515; Barrier Methods 518; Condom (Male) 519; Female Condom (Femidom) 519; Diaphragm 519; Vaginal Contraceptives 520; Fertility Awareness Method 520; Contraceptive Counseling and Prescription 521; Prescription 521; Ongoing Trials and Selective Availability 522; Transcervical Sterilization 522 523 **Operative Obstetrics** Dilatation and Evacuation (D & E) 523; One-stage Operation 523; Two-stage Operation 524; Management of Uterine Perforation 525; Suction Evacuation 525; Vacuum Aspiration 526; ■ Episiotomy 527; • Types 527; • Steps, Postoperative Care 528; • Complications 529; ■ Operative Vaginal Delivery 529; • Forceps 530; • Types of Forceps Operation 530; • Low Forceps Operation 532; Outlet Forceps Operation 535; Midforceps Operation 535; Difficulties in Forceps Operation 535; • Kielland's Forceps 536; • Complications of Forceps Operation 537; • Ventouse 537; • Version 540; External Cephalic Version 540; Internal Version 542; Cesarean Delivery (CD) 542; Indications 543; • Lower Segment CS 544; • Postoperative Care 547; • Classical Cesarean Section 548; • Complications of CS: Intraoperative, Postoperative 549; Destructive Operations 550; Craniotomy 550; Cleidotomy 552; Postoperative Care 552; Symphysiotomy 552 554 Safe Motherhood, Epidemiology of Obstetrics Safe Motherhood 554; Clinical Causes of Maternal Deaths 554; Country Targets 555; Sustainable Development Goals (SDGs) 556; Reproductive and Child Health (RCH) Care 557; Epidemiology of Obstetrics 558; • Maternal Mortality 558; • Maternal Near Miss 561; • Maternal Morbidity 561; Perinatal Mortality 561; Important Causes of Perinatal Mortality and Main Interventions 563;

Stillbirths 563;
 Neonatal Deaths 563

<ul> <li>Intrapartum Fetal Evaluation 565;</li> <li>Methods of Fetal Evaluation 565;</li> <li>Nonreassuring Fetal State (NRFS) 570;</li> <li>Management 570;</li> <li>Shock in Obstetrics 572;</li> <li>Pathophysiology 572;</li> <li>Generothanges 572;</li> <li>Classification of Shock 574;</li> <li>Management of Shock 575;</li> <li>Endotoxic Shock 574;</li> <li>Management in Obstetrics 579;</li> <li>Blood Coardination Disorders in Obstetrics 580;</li> <li>Normal Blood Coagulation 582;</li> <li>Pathology of Acquired Coagulops</li> <li>Investigations 583;</li> <li>Treatment 584;</li> <li>High-risk Pregnancy 585;</li> <li>Management of High-risk</li> </ul>	al 76; ulation thy 582;
---	----------------------------------

#### Medical Ethics 592; Effective Clinical Communication 592; Pregnancy Following Assisted Reproductive Technology (ART) 593; Antibiotic Prophylaxis in Cesarean Section 594; Day-care Obstetrics 594; Legal

and Ethical Issues in Obstetric Practice 594; • The Preconception Counseling Prenatal Diagnostic Techniques 595;

Audit in Obstetrics 595;
 Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine 596;

Stem Cells and Therapies in Obstetrics 596

## Imaging in Obstetrics (USG, MRI, CT, Radiology), Amniocentesis and Guides to Clinical Tests

598

Ultrasound in Obstetrics 598;
 Three-dimensional Ultrasonography 599;
 First Trimester Ultrasonography 599;

• Midtrimester Ultrasonography 601; • Third Trimester Ultrasonography 602; • Intrapartum Sonography 603;

 Magnetic Resonance Imaging (MRI) 603;
 Computed Tomography (CT) in Obstetrics 604;
 Radiology in Obstetrics 604; Amniocentesis 605; Guides to Clinical Tests 606; Tests for Blood Coagulation Disorders 607;

Collection of Blood Sample 607;
 Samples for Blood Sugar Estimation 608;
 Cervical and Vaginal Cytology 608

#### 42 Practical Obstetrics

609

Obstetrics Instruments 609;
 Drugs 620;
 Specimens 622;
 Imaging Studies 627;
 Suture Materials 629

Index

631




Fig. 16.15: Cornual pregnancy.

by laparoscopy/laparotomy. If the pedicle is short and the attachment is wide, hysterectomy may have to be done (Fig. 16.15).

#### **CERVICAL PREGNANCY**

This is a rare (1 in 16,000 pregnancies) variant of ectopic pregnancy when the implantation occurs in the cervical canal at or below the internal os. Erosion of the walls by the trophoblasts occurs resulting in thinning and distension of the canal. The condition is commonly confused with cervical abortion. In cervical pregnancy, the bleeding is painless and the uterine body lies above the distended cervix. Intractable bleeding following evacuation or expulsion of the products brings about suspicion. The morbidity and mortality is high because of profuse hemorrhage (Figs. 16.16A to C).

#### **USG Diagnostic Criteria**

(a) Uterine cavity—empty. (b) Cervix—barrel shaped. (c) GS: located below the internal OS. (d) Absence of 'sliding sign' (in a case with miscarriage, when probe pressure is applied on the cervix, the gestational sac slides against the cervical canal whereas in cervical pregnancy and scar ectopic pregnancy, it does not happen so). (e) Increased blood flow around the GS is seen while using color Doppler.

Clinical diagnostic criteria (Rubin-1983) for cervical pregnancy are—(a) Soft, enlarged cervix equal to or larger than

the fundus. (b) Uterine bleeding following amenorrhea, without cramping pain (90%). (c) Products of conception entirely confined within and firmly attached to endocervix. (d) A closed internal cervical os and a partially opened external os (Figs. 16.16A to C). Confirmation is done by histological evidence of the presence of villi inside the cervical stroma.

#### Management:

■ Medical management: Systemic methotrexate, local injection with KCl. ■ Surgical management: When bleeding is lifethreatening

Surgical procedures used are: • Dilatation and curettage. With or without adjunctive methods: • Uterine artery ligation.

Uterine Artery Embolization (EUA)

#### Other procedures of management:

- Intracervical vasopressin injection.
- Hemostatic cervical sutures on the lateral aspects of the cervix (3 and 9 o'clock position).
- Folley balloon catheter to tamponade bleeding after the curettage.
- Hysteroscopic resection with UAE
- Hysterectomy.

#### Criteria for successful conservative management

- Pregnancy <12 weeks.</li>
- Absence of fetal cardiac activity.
- Low serum beta hCG levels.

#### PREGNANCY OF UNKNOWN LOCATION

No sign of either intra- or extrauterine pregnancy or retained products of conception antransvaginal ultrasound in a woman with a positive pregnancy test.

#### **CESAREAN SCAR PREGNANCY**

Cesarean scar pregnancy is defined as implantation into the myometrial defect in the site of the previous uterine scar (for cesarean delivery). Overall prevalence is 1 in 2500-3000 pregnancies. Outcome: (a) may continue viable pregnancy, or (b) may end in miscarriage within the scar.






**Figs. 16.16A to C:** Cervical pregnancy—hysterectomy done (showing Rubin's diagnostic criteria): **(A)** Globular cervix with partially opened external os; **(B)** Uterus cut opened through the anterior wall to show the huge hemorrhagic mass occupying the cervical canal with empty uterine cavity; **(C)** When the mass was dissected, the cervical wall showed macroscopic evidence of invasion of trophoblastic tissue (confirmed on histology).

USG diagnostic criteria (Figs. 16.17A and B) (Combined TAS and TVS): (a) Empty uterine cavity, (b) GS or solid mass of trophoblast cells located anteriorly at the level of internal OS and embedded at the niche scar, (c) Thin or absent layer of myometrium, (d) Distinct vascular flow on Doppler study, (e) Closed endocervical canal, (f) Yolk sac, embryo, cardiac activity may be seen, (g) Negative 'slide organs' sign.

**Diagnostic features** of cesarean scar pregnancy on MRI are similar to that of USG. MRI is needed when the USG diagnosis is inconclusive. Serum beta hCG level may be useful for management formulation.

**Types:** (a) Type 1 (endogenic)—growing towards the uterine cavity, (b) Type 2 (exogenic)—growing outwards. Risk of rupture and hemorrhage is high in exogenic type.

Treatment options: (a) Associated with high maternal morbidity and mortality, (b) Surgical rather than medical method is found most effective, (c) Live birth following management has been reported (though rare), (d) Medical treatment: Methotrexate



**Figs. 16.17A and B: (A)** Ultrasonographic view of cesarean scar pregnancy. Layer of myometrium is absent over the implantation site (see arrow); **(B)** Cesarean scar pregnancy (exogenic type), causing rupture and hemorrhage (see arrow).

is administered by systemic (IM) or local injection into the gestation sac. (e) Surgical treatment: Evacuation (S/E) or excision of pregnancy by: Open or laparoscopic or hysteroscopic method. Additional hemostatic measures used are: Foley catheter insertion or UAE or uterine artery ligation or hysterectomy (in advanced cases).

#### **HETEROTOPIC PREGNANCY**

Intrauterine pregnancy may be co-existent with tubal or rarely with cervical or ovarian pregnancy. Diagnosis is difficult. Incidence is about 1 in 8,000 pregnancies at present. It is more common following ART procedures.

#### **USG Diagnostic Criteria**

- A. Demonstration of an intrauterine pregnancy and a co-existing ectopic pregnancy,
- B. A higher than expected level of serum beta hCG in relation to gestational age.
- C. There may be persistently raised level of serum beta hCG even following miscarriage or termination of pregnancy.

Management options: The intrauterine pregnancy should be considered in the management plan.

#### **Medical Management**

- A. Methotrexate can be given in a case where: (i) Intrauterine pregnancy is nonviable, (ii) Patient does not wish to continue the pregnancy.
- B. Local injection of potassium chloride or hyperosmolar glucose with aspiration of the sac contents may be done (feticide)—(i) Surgery: Removal of ectopic pregnancy, if the patient is hemodynamically unstable following simultaneous resuscitation. (ii) Expectant management: When heterotopic pregnancy is nonviable.

Rhesus D (Rh D) negative women with ectopic pregnancy should be given anti-D immunoglobulin.



#### > Ectopic Pregnancy

- > An ectopic pregnancy is one in which the blastocyst is implanted and develops outside the normal endometrial cavity.
- The different sites of ectopic pregnancy are: tubal (most common), ovarian, abdominal, cervical and others.
- The common causes of ectopic pregnancy are: salpingitis, PID, contraception failure (IUCD), tubal ligation, ART procedures and tubal surgery.
- Other uncommon sites of ectopic pregnancy are: (a) abdominal pregnancy, (b) ovarian pregnancy, (c) cornual pregnancy, (d) cervical pregnancy, and (e) cesarean scar pregnancy.
- Presentation of a women with ectopic pregnancy includes: abdominal pain, amenorrhea and vaginal bleeding.
- > **Diagnosis** of ectopic pregnancy is made by: positive hCG (either in urine or serum), transvaginal sonography (no intrauterine pregnancy, fluid in the pouch of Douglas and adnexal mass) and laparoscopy/laparotomy is done for confirmation.
- > **Treatment** of ecotopic pregnancy could be surgical or medical. Surgery could be done either by laparoscopy (common) or by laparotomy. Either salpingotomy or salpingectomy is done.
- Ruptured tubal ectopic pregnancy should be managed by simultaneous resuscitation and laparotomy and it is not resuscitation followed by laparotomy.
- > Unruptured tubal ectopic pregnancy could be treated medically with methotrexate once the criteria are fulfilled.
- Prospect of fertility following an ectopic pregnancy: fertility is not adversely affected for a woman without any history of subfertility. Expectant or medical management often gives improved result compared to salpingectomy.

#### GESTATIONAL TROPHOBLASTIC DISEASES (GTD)

**DEFINITION:** Gestational Trophoblastic Disease (GTD) encompasses a spectrum of proliferative abnormalities of trophoblasts associated with pregnancy. The malignant form of GTD is referred as Gestational Trophoblastic Neoplasia (GTN).

CLASSIFICATION: Morphological classification of GTD is less important. Because at present management is largely medical irrespective of histology. Follow-up of patients with GTD again depends on hCG than on histologic diagnosis (Box 16.6). Immunohistochemical and molecular studies are thought to be more important.

Non-gestational trophoblastic disease occurs as a primary choriocarcinoma of the ovary and is probably a teratomatous tumor.

#### **HYDATIDIFORM MOLE** (SYN: VESICULAR MOLE)

#### TYPES: \* Complete \* Incomplete (partial)

The types are categorized on the basis of gross morphology, histopathology and karyotype (Table 16.2). However, unless specified, molar pregnancy relates one with complete mole.

DEFINITION: It is an abnormal condition of the placenta where there are partly degenerative and partly proliferative changes in the young chorionic villi. These result in the formation of clusters of small cysts of varying sizes. Because of its superficial resemblance to hydatid cyst, it is named as hydatidiform mole. It is best regarded as a benign neoplasia of the chorion with malignant potential.

INCIDENCE: There is wide range of geographical and ethnic variation of the prevalence of the condition.

#### Box 16.6: Classification of GTD

- Hydatidiform mole: Complete Partial
- **■** Gestational Trophoblastic Neoplasia (GTN)
- Invasive mole
- Placental site trophoblastic tumor
- **■** Choriocarcinoma

Nonmetastatic disease (confined to the uterus) Metastatic disease:

#### A. Low-risk (good prognosis)

- Disease is present <4 months duration.
- Initial serum hCG level <40,000 mIU/mL.</li>
- Metastasis limited to lung and vagina.
- No prior chemotherapy.
- · No preceding term delivery.

#### B. High-risk (poor prognosis)

- Long duration of disease (>4 months).
- Initial serum hCG >40,000 mIU/mL.
- Brain or liver metastasis.
- Failure of prior chemotherapy.
- Following term pregnancy.
- WHO score >7.

The molar pregnancy is common in oriental countries—Philippines, China, Indonesia, Japan, India, Central and Latin America and Africa. The highest incidence is in Philippines being 1 in 80 pregnancies and lowest in European countries 1 in 752 and USA being about 1 in 2,000. The incidence, in India, is about 1 in 400.

ETIOLOGY: The cause is not definitely known, but it appears to be related to the ovular defect as it sometimes affects one ovum of a twin pregnancy. However, the following factors and hypotheses have been forwarded:

- Its prevalence is highest in teenage pregnancies and in those women over 35 years of age.
- The prevalence appears to vary with race and ethnic origin.
- Faulty nutrition caused by inadequate intake of protein, animal fat could partly explain its prevalence in the oriental countries. Low dietary intake of carotene is associated with increased risk.
- Disturbed maternal immune mechanisms suggested by—(a) Rise in gammaglobulin level in absence of hepatic disease. (b) Increased association with AB blood group which possesses no ABO antibody.
- Cytogenetic abnormality: In general, complete moles have a 46,XX karyotype (85%), the molar chromosomes are derived entirely from the father. The ovum nucleus may be either absent (empty ovum) or inactivated which has been fertilized by a haploid sperm. It then duplicates its own chromosomes after meiosis. This phenomenon is known as androgenesis. Infrequently, the chromosomal pattern may be 46,XY or 45,X.
- The higher the ratio of paternal-maternal chromosomes, the greater is the molar change. Complete moles show 2:0 paternal/maternal ratio whereas partial mole shows 2:1 ratio.
- History of prior hydatidiform mole increases the chance of recurrence (1-4%).

#### PATHOLOGY OF HYDATIDIFORM MOLE

It is principally a disease of the chorion. Death of the ovum or failure of the embryo to grow is essential to develop complete (classic) hydatidiform mole. The secretion from the hyperplastic cells and transferred substances from the maternal blood accumulate in the stroma of the villi which are devoid of blood vessels. This results in distension of the villi to form small vesicles. The distension may also be due to edema and liquefaction of the stroma. Vesicle fluid is interstitial fluid and is almost similar to ascitic or edema fluid, but rich in hCG.

Naked eye appearance (Fig. 16.18): The mass filling the uterus is made of multiple chains and clusters of cysts of varying sizes. There is no trace of embryo or the amniotic sac. Hemorrhage, if occurs, takes place in the decidual space.